StockDuty ← Dashboard Nov 03, 2026 04:47 PM ET
SignalCorporate

Jazz climbs as 2026 revenue guidance boosted

Jazz climbs as 2026 revenue guidance boosted

What happened: Jazz Pharmaceuticals (JAZZ) raised its 2026 revenue forecast and reported Q3 results that beat on the top line. Shares rose about 8% in Tuesday morning trading. Key numbers: 2026 revenue guidance now $4.775B-$4.85B, up from $4.6B-$4.75B prior. Consensus is $4.8B. Stock up ~8%. Why it matters: The raised outlook puts the low end of guidance above the prior range, and the top-line beat accompanied the increase. Coverage: 5 outlets in 24h
Jazz Pharmaceuticals (JAZZ) raised its 2026 revenue forecast and reported Q3 results that beat on the top line. Shares rose about 8% in Tuesday morning trading.
The raised outlook puts the low end of guidance above the prior range, and the top-line beat accompanied the increase.
Sources